Absolute CD4+ T-lymphocyte count as a surrogate marker of pediatric human immunodeficiency virus disease progression

Pediatric Infectious Disease Journal

Volumn 27, Issue 7, 2008, Pages 629-635

  Paintsil, Elijah ^a,b   Ghebremichael, Musie ^c   Romano, Sostena ^b   Andiman, Warren A ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

HIV disease progression; HIV viral load; Pediatrics; Resource limited settings

Indexed keywords

CD4 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE; BIOLOGICAL MARKER;

ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RACE; RELIABILITY; SCHOOL CHILD; TREATMENT RESPONSE; VIRUS LOAD; ADOLESCENT; CD4+ T LYMPHOCYTE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; PRESCHOOL CHILD;

ADOLESCENT; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HIV; HIV INFECTIONS; HUMANS; LONGITUDINAL STUDIES; LYMPHOCYTE COUNT; MALE; VIRAL LOAD;

EID: 50949126367     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181693892     Document Type: Article

References (38)

1. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunode?ciency virus type 1 with zidovudinetreatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
2. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251-265.
3. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA. 2006;296:827-843.
4. O'Brien WA, Hartigan PM, Daar ES, Simberkoff MS, Hamilton JD. Changes in plasma HIV RNA levels and CD4 lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS. Ann Intern Med. 1997;126: 939-945.
5. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunode?ciency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337: 734-739.
6. Mofenson LM, Korelitz J, Meyer WA 3rd, et al. The relationship between serum human immunode?ciency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. J Infect Dis. 1997;175:1029-1038.
7. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count in HIV-infected infants and children. JAMA. 1998;279:756-761.
8. Valentine ME, Jackson CR, Vavro C, et al. Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunode?ciency virus-infected pediatric patients. Pediatr Infect Dis J. 1998;17:18-23.
9. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants infected with human immunode?ciency virus type 1. Women and Infants Transmission Study Group. N Engl J Med. 1997;336:1337-1342.
10. De Rossi A. Virological and immunological response to antiretroviral therapy in HIV-1 infected children: genotypic and phenotypic assays in monitoring virological failure. New Microbiol. 2004;27:45-50.
11. Naver L, Ehrnst A, Belfrage E, et al. Long-term pattern of HIV-1 RNA load in perinatally infected children. Scand J Infect Dis. 1999;31:337-343.
12. Hughes MD, Stein DS, Gundacker HM, Valentine FT, Phair JP, Volberding PA. Within-subject variation in CD4 lymphocyte count in asymptomatic human immunode?ciency virus infection: implications for patient monitoring. J Infect Dis. 1994;169:28-36.
13. Wade AM, Ades AE. Incorporating correlations between measurements into the estimation of age-related reference ranges. Stat Med. 1998;17: 1989-2002.
14. Stein DS, Korvick JA, Vermund SH. CD4 lymphocyte cell enumeration for prediction of clinical course of human immunode?ciency virus disease: a review. J Infect Dis. 1992;165:352-363.
15. Mandy FF, Nicholson JK, McDougal JS. Guidelines for performing single-platform absolute CD4 T-cell determinations with CD45 gating for persons infected with human immunode?ciency virus. Centers for Disease Control and Prevention. MMWR Recomm Rep. 2003; 52:1-13.
16. Lyamuya EF, Kagoma C, Mbena EC, et al. Evaluation of the FAC-Scount, TRAx CD4 and Dynabeads methods for CD4 lymphocyte determination. J Immunol Methods. 1996;195:103-112.
17. Sherman GG, Galpin JS, Patel JM, Mendelow BV, Glencross DK. CD4 T cell enumeration in HIV infection with limited resources. J Immunol Methods. 1999;222:209-217.
18. Cassens U, Gohde W, Kuling G, et al. Simpli?ed volumetric ?ow cytometry allows feasible and accurate determination of CD4 T lymphocytes in immunode?cient patients worldwide. Antivir Ther. 2004;9: 395-405.
19. Diagbouga S, Chazallon C, Kazatchkine MD, et al. Successful implementation of a low-cost method for enumerating CD4 T lymphocytes in resource-limited settings: the ANRS 12-26 study. AIDS. 2003;17: 2201-2208.
20. Andiman WA, Simpson BJ, Olson B, Dember L, Silva TJ, Miller G. Rate of transmission of human immunode?ciency virus type 1 infection from mother to child and short-term outcome of neonatal infection. Results of a prospective cohort study. Am J Dis Child. 1990;144:758-766.
21. Simpson BJ, Andiman WA. Dif?culties in assigning human immunode?ciency virus-1 infection and seroreversion status in a cohort of HIV-exposed in children using serologic criteria established by the Centers for Disease Control and Prevention. Pediatrics. 1994;93:840-842.
22. Centers for Disease Control (CDC). Classi?cation system for human immunode?ciency virus (HIV) infection in children under 13 years of age. MMWR Morb Mortal Wkly Rep. 1987;36:225-230;235-236.
23. Dunn DT, Brandt CD, Krivine A, et al. The sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period and the relative contributions of intra-uterine and intra-partum transmission. AIDS. 1995;9: F7-F11.
24. Littell RC, Henry PR, Ammerman CB. Statistical analysis of repeated measures data using SAS procedures. J Anim Sci. 1998;76:1216-1231.
25. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. Lancet. 2005;366:1868-1874.
26. HIV Paediatric Prognostic Markers Collaborative Study. Predictive value of absolute CD4 cell count for disease progression in untreated HIV-1-infected children. AIDS. 2006;20:1289-1294.
27. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunode?ciency virus infection. N Engl J Med. 1993;328:327-335.
28. Nkengasong JN, Adje-Toure C, Weidle PJ. HIV antiretroviral drug resistance in Africa. AIDS Rev. 2004;6:4-12.
29. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach. Executive summary. IAPAC. 2002;8:168-175.
30. Colebunders R, Moses KR, Laurence J, et al. A new model to monitor the virological ef?cacy of antiretroviral treatment in resource-poor countries. Lancet Infect Dis. 2006;6:53-59.
31. Kent DM, McGrath D, Ioannidis JP, Bennish ML. Suitable monitoring approaches to antiretroviral therapy in resource-poor settings: setting the research agenda. Clin Infect Dis. 2003;37:S13-S24.
32. Florence E, Dreezen C, Schrooten W, et al. The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment. Int J STD AIDS. 2004;15:538-542.
33. Lugada ES, Mermin J, Kaharuza F, et al. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol. 2004;11:29-34.
34. Florence E, Lundgren J, Dreezen C, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med. 2003;4:255-262.
35. Rodriguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006;296:1498-1506.
36. European Collaborative Study. Are there gender and race differences in cellular immunity patterns over age in infected and uninfected children born to HIV-infected women? J Acquir Immune De?c Syndr. 2003;33: 635-641.
37. Bunders M, Cortina-Borja M, Newell ML. Age-related standards for total lymphocyte, CD4 and CD8 T cell counts in children born in Europe. Pediatr Infect Dis J. 2005;24:595-600.
38. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS. 2001;15:761-770.